Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/15/2025

Cardiovascular Disease Management

Definition and Diagnosis of Left Ventricular Hypertrophy

  • The European Society of Cardiology recommends that ECG-LVH is defined by increased voltages and repolarization abnormalities, with common criteria including Sokolow-Lyon index (SV1 + RV5 >3.5 mV) or Cornell voltage product (>244 mV*ms) 1, 2
  • Echocardiography is more sensitive than ECG for detecting LVH, according to the European Heart Journal 2, 3
  • Secondary ST-T abnormalities often accompany LVH and provide major support to the diagnosis, as stated by the American College of Cardiology 4
  • Left ventricular hypertrophy (LVH) is classified into concentric and eccentric types based on relative wall thickness (RWT), with concentric LVH having RWT ≥0.42 and eccentric LVH having RWT ≤0.42, both with increased LV mass, as defined by the European Heart Journal 5
  • Normal values for LV mass index (LVMI) are ≤115 g/m² (linear method) or ≤102 g/m² (2D method) for men, and ≤95 g/m² (linear method) or ≤88 g/m² (2D method) for women, according to the European Heart Journal 6

Risk Factors and Pathophysiology of Left Ventricular Hypertrophy

  • Hypertension is the predominant cause of LVH in adults, especially in older women, and creates increased left ventricular output impedance and intramyocardial wall tension, leading to concentric remodeling with parallel addition of sarcomeres, resulting in increased wall thickness and left ventricular mass, as reported by the European Heart Journal 1, 7
  • Hypercholesterolemia contributes to atherosclerotic changes that can increase cardiac workload and is associated with increased risk of LVH, according to the European Heart Journal 1
  • Age itself is a determinant of LVH, with postmenopausal women having increased cardiovascular risk that may contribute to LVH, as stated by the American Heart Association 7
  • Prolonged hypertension causes left ventricular hypertrophy primarily through increased systolic wall stress, which triggers concentric remodeling with parallel addition of sarcomeres, widening of cardiac myocytes, and increased myocyte cross-sectional area, ultimately leading to increased wall thickness and left ventricular mass 5
  • Chronic hypoxemia, hypercarbia, and acidosis can stimulate the renin-angiotensin system, elevating afterload and contributing to hypertrophy 8

Prognosis and Treatment of Left Ventricular Hypertrophy

  • LVH is an independent predictor of cardiovascular events and mortality, with each 50 g/m² increment in LV mass increasing the hazard ratio for sudden cardiac death by 1.45, as reported by the European Heart Journal 1, 7
  • Untreated LVH can progress to dilated cardiomyopathy and heart failure, but aggressive blood pressure control is essential for LVH regression, and ACE inhibitors have shown consistent reduction in LV mass, according to the American Heart Association 3
  • Treating hypercholesterolemia is crucial, with statins expected to provide 30-40% relative risk reduction, and lipid management should be aggressive in patients with LVH, as recommended by the European Heart Journal 1
  • Weight reduction, sodium restriction, and regular physical activity are recommended, with physical activity of 60-90 minutes per week reducing CHD mortality by about 50%, as stated by the American Heart Association 3
  • The American College of Cardiology recommends identifying and treating underlying causes, such as aggressive blood pressure control if hypertensive, and evaluating for aortic stenosis or other valvular disease, as part of managing borderline concentric LVH 5
  • Risk factor modification, including lifestyle changes (weight reduction, sodium restriction, exercise) and management of comorbidities (diabetes, dyslipidemia), is crucial in managing borderline concentric LVH, as suggested by the European Society of Cardiology 9

Management and Follow-up of Left Ventricular Hypertrophy

  • Asymptomatic patients with borderline LV size and preserved function should have clinical follow-up yearly and echocardiography every 2 years, as advised by the European Society of Cardiology 10
  • Asymptomatic patients with borderline severe findings should have clinical evaluation every 6 months and echocardiography every 12 months, with closer follow-up for borderline values, as recommended by the European Society of Cardiology 10
  • Serial echocardiography is recommended for borderline LV dimensions, with 2 consecutive measurements obtained before making management decisions, as advised by the American Heart Association 11
  • Consider normalization for body size, especially in smaller patients, as recommended by the American Heart Association 11
  • Additional imaging, such as cardiac MRI, may be considered for more precise measurements, especially for complex geometry, as suggested by the European Society of Cardiology 12

Complications and Consequences of Left Ventricular Hypertrophy

  • Concentric LVH has several important functional consequences, including diastolic dysfunction, coronary perfusion abnormalities, increased sensitivity to ischemic injury, and atrial contribution to ventricular filling 11
  • Concentric LVH carries significant risks, including increased morbidity and mortality, risk of progression to heart failure, and transition from compensated hypertrophy to heart failure, often with an increase in LV end-diastolic and end-systolic volumes and decreased ejection fraction 13, 5
  • Failure to normalize for body size, especially in smaller patients and women, can lead to inaccurate assessments, as warned by the American Heart Association 11
  • Overreliance on single measurements can lead to incorrect management decisions, as cautioned by the American Heart Association 11
  • Measurement errors can occur if the M-mode cursor is not properly aligned perpendicular to the LV long axis, and asymmetric hypertrophy can lead to overestimation of LV mass using linear measurements, as noted by the European Heart Journal 6

REFERENCES

8

statement on the care of the child with chronic lung disease of infancy and childhood. [LINK]

American Journal of Respiratory and Critical Care Medicine, 2003